Kornimate/medical-research-clean huggingface dataset:
impact of validated diagnostic prediction model of acute heart failure in the emergency department

Conditions: Dyspnea; Acute Heart Failure; Shortness of Breath

Summary: the purpose of this study is to evaluate a validated diagnostic prediction model in the appropriate diagnosis of acute heart failure (ahf) in patients presenting at the emergency department with undifferentiated dyspnea.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * presentation to the ed with undifferentiated shortness of breath exclusion criteria: * dyspnea of obvious cause, e.g. chest trauma, obvious clinical exacerbation of known chronic obstructive disease * obvious pulmonary edema in a patient with a known diagnosis of hf and recently admitted to hospital for hf * clinician does not plan to treat for ahf at all, but rather to pursue other causes of dyspnea (i.e., probability of ahf ≤ 20%) * clinician plans to treat for ahf and not to pursue other causes of dyspnea (i.e., probability of ahf ≥ 80%) * acute coronary syndrome within one month * chronic renal failure (serum creatinine ≥ 250 mol/l) * anticipated life expectancy \< 6 months due to non-cardiovascular causes * participation in another interventional outcome trial * inability to obtain informed consent, including inability of patient to understand english
prevention of eating disorders through optimization of protective factors

Conditions: Body Dissatisfaction; Eating Disorders

Summary: the goal of thin randomized controlled trial is to investigate the efficacy of a prevention program for reducing the incidence of eating disorders among youth (15-20). we target youth at these ages who experience a subjective sense of body dissatisfaction, and are thus at increased risk of developing an eating disorder. the prevention program is based on improving protective factors such as body appreciation, body image flexibility, intuitive eating, and acceptance. it will be compared to a credible placebo (expressive writing).

research area and aims: eating disorders (eds) are common and cause significant morbidity and mortality. due to stigma, only 25% seek help and only 50% fully recover after receiving treatments. large-scale prevention is urgently needed to reduce the emergence and burden of eds at a population level. however, current prevention programs do not meet requirements for efficient and economically attractive large-scale implementation. the main aim of this project is to investigate the efficacy and cost-effectiveness of a scalable, brief, and interactive prevention program based on reinforcement of protective factors against eds using a randomized controlled design. a focus on protective factors disrupts the processes by which risk factors increase the probability for eds to emerge and minimizes the risks for stigmatization. research questions: 1. how effective is an internet-based prevention program, that reinforces protective factors against eds, in reducing the onset of eds 6, 12, 24, and 36 months post-intervention? 2. does the intervention reduce the incidence of eds through enhancement of specifically targeted protective factors (mediators)? 3. is prevention of eds based on reinforcement of protective factors cost-effective? 4. how do the participant experience their participation in these two interventions? other research questions concern gender differences in enrollment and compliance, potential moderators of outcome, participation in booster sessions, and potential risk for stigma.

Eligibility criteria:
inclusion criteria: youth and young people (15-20 years) with a subjective experience of body dissatisfaction. exclusion criteria: indications of depression, or suicidality, as well as presence of an eating disorder, or other conditions that may require medical attention, or conditions that makes it impossible to complete the intervention (e.g., not being able to read and write in swedish).

Keywords: eating disorders body dissatisfaction risk factors buffering factors incidence efficacy cost-effectiveness
fertility surgery, prospective analysis

Conditions: Endometriosis

Summary: from september 2006 a prospective cohort study is conducted among all patients operated at the leuven university fertility centre to evaluate clinical and economical outcome after co2 laser laparoscopic fertility surgery.

the main outcome measurements are postoperative complications, pain, quality of life, sexual satisfaction, economic life circumstances, cumulative pregnancy rate and cumulative recurrence rate of endometriosis.

Eligibility criteria:
inclusion criteria: * all patients * operated at the leuven university fertility centre of the department of obstetrics and gynaecology of the university hospitals leuven, leuven,belgium, * from september 2006 to august 2008. exclusion criteria: * patients of other than the dutch language

Keywords: endometriosis fertility surgery quality of life pain sexual function health economics recurrence pregnancy
validation of the gugging swallowing screen for the intensive care unit

Conditions: Dysphagia

Summary: aetiology of dysphagia after extubation is unknown and considered to be multifactorial. use of a standardized dysphagia- screening permits an early diagnosis. this study is to evaluate a new guss (gugging swallowing screen) tool with multi-consistency check for intensive care patients (guss-icu) with dysphagia. the concurrent validity (in terms of sensitivity and specificity) of the guss-icu is analyzed in comparison to the flexible endoscopic evaluation of swallowing (fees).

aetiology of dysphagia after extubation is unknown and considered to be multifactorial. use of a standardized dysphagia- screening permits an early diagnosis. this study is to evaluate a new guss (gugging swallowing screen) tool with multi-consistency check for intensive care patients (guss-icu) with dysphagia. the concurrent validity (in terms of sensitivity and specificity) of the guss-icu is analyzed in comparison to the flexible endoscopic evaluation of swallowing (fees). the guss-icu with multi-consistency check includes an indirect and a direct swallowing attempt. in indirect swallowing, the vigilance is first assessed on the basis of the rass score (richmond agitation-sedation scale), the presence of a stridor, the effectiveness of coughing and screeting, the possibility of swallowing saliva, drooling (saliva) and the change of voice after swallowing. if six points are reached, one can immediately proceed to the direct swallowing attempt. unlike the original guss, the new guss-icu direct swallowing test consists of 4 subtests with pulpy, liquid, solid and mixed solid-liquid consistency. the mixed solid-liquid consistency has been supplemented, as mixed consistencies require a more complex swallowing function with increased tongue- and lip coordination.

Eligibility criteria:
inclusion criteria: * patients treated in icu with intubation time of at least 24 hours * richmond agitation-sedation scale (rass)-score of 0 (alert and calm) to 2 (agitated) * inclusion in study not earlier than 1 hour after extubation * mini-mental-state (mms) score \>/=24 * signed informed consent exclusion criteria: * not capable to follow study procedures (language problems, mental disorder) * end of life- patients

Keywords: gugging swallowing screen - icu (guss-icu) gugging swallowing screen (guss) multi-consistency check flexible endoscopic evaluation of swallowing (fees)
safety and efficacy of firmagon® (degarelix) for injection

Conditions: Prostate Cancer

Summary: the purpose of this study is to assess the safety and efficacy of firmagon® (degarelix) for injection under the conditions of general clinical practice in korea.


Eligibility criteria:
inclusion criteria: * patients who are eligible for the treatment of firmagon® (degarelix) for injection according to the approved product label, and firmagon® (degarelix) treatment decided before study enrolment. moreover, patient should have not previously received firmagon® (degarelix) for injection before the study commencement date at each site. - indication: treatment of advanced, hormone-dependent prostate cancer. exclusion criteria: * patients with previous or concurrent known hypersensitivity to any component of the drug.
clinical and metabonomics study on the treatment of heart failure after myocardial infarction with modified wenxin decoction

Conditions: Heart Failure; Myocardial Infarction

Summary: to elucidate the efficacy and safety of weixin decoction in the treatment of heart failure after myocardial infarction.

to elucidate the long-term protective effect of flavored wenxin decoction on heart failure after myocardial infarction. to elucidate the effective components in the treatment of heart failure and the mechanism of metabolism regulation.

Eligibility criteria:
inclusion criteria: * 18-75 years old； * a history of acute myocardial infarction； * cardiac function ⅱ - ⅲ level； * lvef 50% or less; * nt-probnp level ≥ 450 pg/ ml； * all men and women can sign the informed consent form. exclusion criteria: * coronary artery bypass grafting was performed within 12 weeks； * undergo or possibly undergo cardiac resynchronization therapy; * primary valvular disease, left ventricular outflow tract obstruction, myocarditis, aneurysm, uncontrolled severe arrhythmia, cardiogenic shock, unstable angina pectoris, or acute myocardial infarction; * having a serious primary liver, kidney or blood system disease or having a serious mental illness or a systemic disease that is out of control; * serum creatinine \> 194.5 mol/l or serum potassium \> 5.5mmol /l; * the level of alanine aminotransferase or alkaline phosphatase is 1.5 times of the normal upper limit of \>; * abnormal blood pressure control, systolic blood pressure exceeding 180mmhg or diastolic blood pressure exceeding 110mmhg; * pregnancy or lactation; known or suspected allergy to research drugs; to receive another investigational drug within 30 days of randomization or to be unwilling or unable to provide written consent.

Keywords: traditional chinese medicine
effectiveness of a 6-week hippotherapy program in children with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the prevalence of autism spectrum disorders (asd) has increased dramatically in the last decade. the increasing occurrence of asd creates an imperative need to test the effectiveness and efficacy mechanisms of appropriate interventions. hippotherapy (hpot) is a treatment option that has been show beneficial for children with asd as well as other children with developmental disorders. the current projects focuses on understanding the mechanisms of hpot efficacy and evaluating a short-term hpot program for children with asd.

the incidence of autism spectrum disorders (asd) has increased dramatically in the last decade. the latest report from the centers for disease control and prevention state that 1 in 59 children are being diagnosed with asd and it is four times more prevalent in boys than girls. common treatments for children with asd are applied behavioral therapy, occupational and speech therapy, which are used solely or in combination. hippotherapy (hpot) is another treatment option that has been shown to positively impact various aspects of behavior. this pilot project aims to determine the effects of a 6-week hpot program on movement and social behavior of children with asd and to investigate the underlying mechanisms of why hpot is successful for asd through the coupling of physiological and temperamental responses between horse and rider. the approach involves examining these skills pre, during, and post hpot intervention in children diagnosed with asd. a group of aged matched children with typical development will serve as the control group. innovative measures of physiological coupling and temperament between horse and rider as well as objective and quantitative measures of movement and social behavior and caregiver perception will be collected. the investigators anticipate that following completion of the proposed study, they will provide the necessary foundation to understand the mechanisms of hpot, and thus provide a new framework to test clinical trials of hpot and human-animal interaction, and ultimately improve the lives of those diagnosed with asd and their families.

Eligibility criteria:
for the children with autism spectrum disorders: inclusion criteria: 1. diagnosis of asd based upon the autism diagnostic observation schedule and parent interview, 2. medical approval for participation in the hpot activity, 3. no other medical or psychiatric diagnoses besides asd 4. tolerate helmet on head and attachments of the movement and heart rate sensors. the inclusion criteria for the td children will be: 1. no diagnosis or family history of asd 2. no other neurodevelopmental or musculoskeletal disorder 3. tolerate helmet on head and attachments of the movement and heart rate sensors. 4. medical approval for participation in the hpot activity, exclusion criteria: 1. under 5 years of age or over 10 years of age 2. has a serious comorbid medical diagnosis 3. major vision or hearing impairments 4. severe behavioral problems 5. an orthopedic or genetic diagnosis
endometriosis, food consumption and fertility

Conditions: Endometriosis

Summary: to investigate parameters related to fertility in women with endometriosis in relation to food items.

the study has been reviewed and accepted by the legal registrations in denmark (the regional committee on biomedical research ethics and the danish dataprotection agency). the data will be anonymous and kept as described by the danish register law.

Eligibility criteria:
inclusion criteria: * fertility patients exclusion criteria: * mental challenges
study of transcatheter tricuspid annular repair

Conditions: Tricuspid Regurgitation

Summary: the purpose of the study is to evaluate the safety and performance of the mia minimally invasive annuloplasty device in patients with chronic functional tricuspid regurgitation.

the purpose of the study is to evaluate the safety and performance of the mia minimally invasive annuloplasty device in patients with chronic functional tricuspid regurgitation. the study is a prospective, multi-center safety and performance study. enrolled subjects will be assessed for clinical follow-up at 1 month, 6 months, and 1 year post implant procedure.

Eligibility criteria:
inclusion criteria: 1. chronic functional tricuspid regurgitation (ftr) with a minimum of moderate tricuspid regurgitation (2-4) 2. age≥18 and ≤85 years old 3. new york heart association (nyha) class ii, iii or ambulatory iv 4. left ventricular ejection fraction (lvef) ≥30% 5. undergoing cardiac surgical procedure with the planned use of cardiopulmonary bypass (surgical arm only) 6. functional tricuspid valve regurgitation pathology with a structurally normal valve; and tricuspid valve annular diameter ≥ 40 mm (or 21 mm/m2) and ≤55 mm (or 29 mm/m2) or 2-4 + ftr 7. patient provides written informed consent before any study-specific tests or procedures are performed 8. patient is willing and able to comply with all specified study evaluations exclusion criteria: 1. pregnant or lactating female 2. severe uncontrolled hypertension (sbp ≥ 180 mmhg and/or dbp ≥ 110 mmhg) 3. previous tricuspid valve repair or replacement 4. myocardial infarction or known unstable angina within the 30-days prior to the index procedure 5. any pci within 30 days prior to the index procedure or planned 3 months post the index procedure 6. life expectancy of less than 12-months 7. severe right heart dysfunction 8. pulmonary hypertension with pa mean 2/3 rd map 9. active systemic infection 10. pericardial infection 11. any clinical evidence that the investigator feels would place the patient at increased risk with the deployment of the device 12. co-morbid conditions that place the subject at an unacceptable surgical risk (e.g. severe chronic obstructive pulmonary disease, hepatic failure, cardiac disease, autoimmune disorders or conditions of severe immunosuppression) 13. untreated coronary artery disease (cad) requiring revascularisation unless cabg procedure is concomitant with mia tricuspid annular repair (surgical arm only) 14. haemodynamic instability: systolic blood pressure \<90mmhg without reduction of afterload, shock, need for inotropic medication or iabp 15. active peptic ulcer or gastrointestinal (gi) bleeding in the past 3 months 16. cerebrovascular event within the past 6 months 17. history of mitral/tricuspid endocarditis within the last 12 months 18. organic tricuspid disease 19. contraindication or known allergy to device's components, aspirin, anti-coagulation therapy or contrast media that cannot be adequately premeditated 20. known alcohol or drug abuser 21. currently participating in the study of an investigational drug or device
safety and efficacy of lumigan® rc versus duotrav® in patients who require further intraocular pressure (iop) reduction

Conditions: Glaucoma, Open-Angle; Ocular Hypertension

Summary: this non-inferiority study will assess safety and efficacy of lumigan® rc (bimatoprost ophthalmic solution 0.01%) versus duotrav® (travoprost 0.004%/timolol 0.5% combination ophthalmic solution) in patients previously on travatan® z (travoprost ophthalmic solution 0.004%) monotherapy.


Eligibility criteria:
inclusion criteria: * open angle glaucoma or ocular hypertension * best corrected visual acuity of 20/100 or better in both eyes exclusion criteria: * ocular surgery within 3 months, or anticipated ocular surgery within 12 weeks * previous treatment with lumigan® rc or duotrav® * history of lasik, lasek, rk or prk in the study eye(s) * active ocular inflammation
ventilatory support associated with exercise in heart failure

Conditions: Heart Failure

Summary: due to the symptoms of heart failure (hf), as dyspnea and fatigue, patients have a reduced functional capacity, evidenced during usual daily activities and exercises. the cardiac rehabilitation with emphasis on resistance and aerobic exercises performed in the same session (concurrent training), can be added to pharmacological treatment as improvement strategy in functional capacity and quality of life.

a randomized clinical trial, divided into two stages will be held. in step 1 the function will be assessed by the 6-minute walk test, spirometry, and questionnaires to evaluate quality of life. after fulfilled the series of assessments individuals will be randomly divided into two groups, with group 1 (control) will hold only one interval aerobic exercise program on treadmill and group 2 (intervention) will hold a combined exercise program for prior use of ventilatory support noninvasive. for both groups will be held an aerobic exercise program associated with resistance exercise for 12 weeks. the first two weeks will be considered in period. in the 10 weeks following both groups maintain the preset exercise program gradually. in the intervention group will be added before the exercise program the use of noninvasive ventilation for 30 minutes.

Eligibility criteria:
inclusion criteria: * will be included 60 patients of both sexes, adults with medical diagnosis divided into two groups: group a consisted of 30 patients use non-invasive ventilation added to interval training and group b consisted of 30 patients also only use interval training. exclusion criteria: * will be excluded from the study patients who have chest pain (angina), arrhythmias, spo2 ≤ 90%, hypertension or hypotension, neurological or osteoarticular disease preventing the ambulation of these individuals.
inhaled no in ipf and copd during 6 minute walk test

Conditions: COPD; IPF; Inhaled Nitric Oxide; Six Minute Walk Test; Oxygen Saturation

Summary: our objective is to evaluate the influence of inhaled no on the saturation and exercise capacity of patients with copd and ipf. each participant will undergo two six minute walk tests, one with inhaled no and the other with placebo.

this is a randomiized, placebo controlled trail that will evaluate the influence of inhaled no (ino) on the saturation and exercise capacity of patients with copd and ipf. all patients will sign a consent form before enrolment. each patient will undergo two six-minute walk tests. whether the ino will be used in the first or the second trial will be determined by computer generated randomization with random numbers sealed in opaque envelops. for the placebo 6-minute test we will use placebo cartridges in the ino generator, for ino 6-minute test we will use no cartridges. the treatment with ino or placebo will start 20 minutes before the 6-minute walk test and will end at the end of the 6-minute walk test. between tests a time interval of at least 60 minutes will be kept. during the test, the patients' pulse and saturation level will be monitored with a pulse oximetry. the data will be recorded continuously from baseline to 5 minutes after the test is over. the distance the patient walked will also be recorded. patients that require supplemental oxygen will perform the tests with oxygen supplementation. dosing the no dosing will be fixed. the first 10 patients will be treated with ino at a dose of 45 parts per million (ppm) per kilogram (kg). from patient 10 to 20 a dose of 75 ppm per kg will be given and from patient 20-100 a dose of 115 ppm per kg will be given.

Eligibility criteria:
inclusion criteria: 1. patients with copd with disease severity of gold stage 3-4 2. patients with ipf with a forced vital capacity under 80% and a diffusion capacity under 60% 3. ambulatory patients that can perform a 6-minute walk test exclusion criteria: 1. patients with moderate to severe heart failure - ef \< 40% 2. patients with severe pvd or scleroderma
the study of infrared imaging on breast cancer

Conditions: Breast Neoplasms

Summary: breast cancer can cause focal temperature increase on the breast skin due to vasodilatation mediated by no secretion from cancer cells. our study is to evaluate this situation and to assess the diagnostic efficacy of infrared imaging (thermography)on breast cancer.

malignant breast neoplasms can secrete no to induce focal vasodilatation and increased blood flow and angiogenesis to the tumor, thus increase the focal temperature, which can be evaluated by breast thermography (infrared imaging). we will evaluate the efficacy of infrared imaging for detection and diagnosis of breast cancer, and if infrared imaging can effectively differentiate malignant from benign breast dieases and the sensitivity, specificity, false-negative rate will also be estimated.

Eligibility criteria:
inclusion criteria: * normal group: women who has normal mammograms or ultrasound in 6 months abnormal group: women who has suspicious findings on mammograms or ultrasound in recent 6 months exclusion criteria: * women who don't fit the above inclusion criteria

Keywords: breast neoplasms diagnosis